SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study

Shares of Cassava Sciences (SAVA) plunged 32.1% on Tuesday after the company announced that its lead pipeline candidate, simufilam, failed to meet the prespecified co-primary endpoints in the second late-stage study for Alzheimer’s disease (AD). Simufilam is SAVA’s proprietary, investigational oral small molecule that targets the filamin A protein.Cassava released top-line results from the phase III REFOCUS-ALZ study, which evaluated simufilam in patients with mild-to-moderate AD. Treatment with the drug fa ...